CRESCENT BIOPHARMA, INC. — Form 8-K
Filed July 30, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 58/100
What the filing says
Crescent Biopharma completed a July 2026 public offering raising $143.7M gross proceeds ($133.5M net), bringing pro forma cash to $305.1M and extending expected cash runway into H2 2028. The company is advancing three clinical programs: CR-001 (PD-1 x VEGF bispecific) in global Phase 1/2 ASCEND trial with proof-of-concept data expected Q1 2027; CR-002 (PD-L1-targeted ADC) expected to initiate H2 2026; and CR-003 (ITGB6-targeted ADC) enrolling in China with data expected Q1 2027. Q2 2026 R&D expenses were $19.4M (vs. $12.1M prior year); net loss was $24.8M; pro forma shares outstanding were 43.5M.
Why this rating
Funding extends runway past key 2027 catalysts, reducing near-term dilution risk. Relative to $177M market cap, $143.7M raise is ~81% of market value—material but expected for clinical-stage biotech. Multiple data readouts in 2027 provide upside catalysts. Execution risk remains high.
See more from July 30, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.